Introduction {#S1}
============

Clinical Presentation {#S1-1}
---------------------

This individual has been reported within a larger cohort study (subject 27.1), and we now describe the detailed clinical and genomic information concerning the case ([@B1]). The patient is a 30-year-old female of Mexican-American descent who presented with a clinical history of susceptibility to infections that suggested the presence of an underlying primary immunodeficiency disease (PIDD). She developed recurrent otitis media and upper respiratory tract infections starting at 3 months of age, and from 3 years of age she had difficulty with severe, recurrent warts. Repeated episodes of pneumonia began at the age of 7 years, resulting in chronic lung disease and bronchiectasis. At the age of 10 years, she developed chickenpox, which was noted to be more severe than in her sisters, who had concurrent symptoms. At the age of 11 years, she was diagnosed with cryptococcal meningitis. She was treated with fluconazole for several weeks as an inpatient and 4 months as an outpatient. Upon discontinuation of treatment, severe, recurrent episodes of meningitis rapidly ensued, resulting in hydrocephalus and ventriculo-peritoneal (VP) shunt placement. This complication was associated with damage of her vision, rendering her legally blind. The patient was then placed on daily fluconazole and intravenous immunoglobulin (IVIG) prophylaxes and subsequently demonstrated persistent serum cryptococcal antigen positivity but no clinical disease or further life-threatening illnesses. In adult life, she developed recurrent human papilloma virus (HPV)-associated oral and cutaneous lesions. She also developed low-grade squamous intraepithelial lesions of the cervix that were attributed to HPV infection. The cervical dysplasia required localized surgical resection. Due to poor response of the other HPV-associated lesions to topical antiviral therapy, interferon-gamma (IFN-γ) treatment was initiated, producing resolution of the oral disease. The cutaneous problems persisted, however. Many of these lesions transformed to squamous cell carcinomas, causing disfigurement due to numerous resections and destructive topical treatments. Treatment for the progressive skin disease included an option for combined surgery and radiotherapy, which was deferred due to the absence of a specific immunologic diagnosis.

Laboratory Test Results {#S1-2}
-----------------------

At the time of the cryptococcal meningitis diagnosis, the patient was evaluated by an immunologist outside of our institutions and diagnosed with combined immunodeficiency characterized by low serum IgG levels (Table [1](#T1){ref-type="table"}) and T cell deficiency. DNA PCR testing excluded HIV infection. Although she was subsequently placed and maintained on IVIG replacement, no further immunologic testing was performed until she was transferred to our care at 21 years of age. At that time, she began to receive regular immunologic evaluations, and the T cell defects were observed to have persisted (Table [1](#T1){ref-type="table"}). Immunophenotyping demonstrated variable T cell lymphopenia, predominantly involving the CD8^+^ subset ([@B2]). T cell proliferative responses were measured using isolated peripheral blood mononuclear cells cultured in microwell plates loaded with 10-fold dilutions of mitogens or specific antigens. The responses were enumerated in terms of counts per minute (cpm) of tritiated thymidine incorporation. These tests showed decreased T cell activity toward mitogens, particularly at lower concentrations. The responses to antigens were very low, as well, but could not be interpreted due to lack of recent immunization (on IgG supplementation) or exposure (to *Candida*). Evaluation of natural killer (NK) cell function showed abnormal CD107a mobilization, suggesting poor NK cell degranulation (Table [1](#T1){ref-type="table"}).

###### 

**Immunologic studies in a patient with *ZAP70* and *RNF168* variants**.

                                         Normal reference                                                                                                                                                       
  -------------------------------------- ---------------------- -------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  Age (years)                                                   11                   21                                       27                                       28                                       29
  **Immunoglobulins**                                                                                                                                                                                           
  IgG (mg/dL)                            641--1,353             \<400                1,020[^a^](#tfn1){ref-type="table-fn"}   1,320[^a^](#tfn1){ref-type="table-fn"}   1,534[^a^](#tfn1){ref-type="table-fn"}   1,375[^a^](#tfn1){ref-type="table-fn"}
  IgA (mg/dL)                            66--295                                     111                                      102                                      ND                                       ND
  IgM (mg/dL)                            40--180                                     124                                      94                                       ND                                       ND
  IgE (IU/mL)                            0--100                                      ND                                       \<1                                      ND                                       \<4
  **Lymphocyte subsets**                                                                                                                                                                                        
  Lymphocytes (cells/mm^3^)                                                          952                                      1,058                                    609                                      1,023
  Total CD3^+^ (cells/mm^3^)             798--2,594                                  750                                      1,342                                    524                                      952
  CD3^+^CD4^+^ (cells/mm^3^)             579--1,841                                  604                                      1,049                                    443                                      508
  CD3^+^CD8^+^ (cells/mm^3^)             184--855                                    84                                       205                                      55                                       133
  CD4^+^:CD8^+^ T cell ratio             1.13--3.5                                   7.2                                      5.1                                      8.1                                      3.8
  CD16^+^/CD56^+^ (cells/mm^3^)          89--472                                     119                                      128                                      12                                       152
  CD19^+^ (cells/mm^3^)                  63--461                                     134                                      126                                      49                                       95
  **Proliferation testing (cpm)**                                                                                                                                                                               
  PHA (10 µg/mL)                         163,507--415,087                            47,124                                   62,544                                   82,419                                   ND
  PHA (1.0 µg/mL)                        35,494--225,107                             338                                      4,405                                    ND                                       ND
  ConA (50 µg/mL)                        80,718--286,866                             14,454                                   83,446                                   ND                                       ND
  ConA (5.0 µg/mL)                       28,998--108,585                             101                                      29,298                                   ND                                       ND
  PWM (100 ng/mL)                        37,006--157,955                             15,176                                   39,050                                   ND                                       ND
  PWM (10 ng/mL)                         24,369--94,311                              1,271                                    11,994                                   ND                                       ND
  *Candida* antigen                      ≥2,000                                      2                                        209                                      71                                       ND
  *Diphtheria* antigen                   ≥2,000                                      ND                                       48                                       ND                                       ND
  Tetanus antigen                        ≥2,000                                      8                                        0                                        ND                                       ND
                                                                                                                                                                                                                
  **Advanced testing**                   **Normal reference**   **Patient result**                                                                                                                              
                                                                                                                                                                                                                
  CD107a mobilization assay                                                                                                                                                                                     
  Age (years)                                                   26                                                                                                                                              
  CD107a% expression                     11--35%                5%                                                                                                                                              
  CD107a median fluorescence intensity   207--678               121                                                                                                                                             
  **Colony survival assay**                                                                                                                                                                                     
  Age (years)                                                   28                                                                                                                                              
  Patient survival fraction              37--63%                8%                                                                                                                                              
  Radiosensitive range                   7--21%                                                                                                                                                                 

*^a^On IgG supplementation*.

*ConA, concanavalin A; ND, not tested; PHA, phytohemagglutinin; PWM, pokeweed mitogen*.

At 28 years of age (Table [1](#T1){ref-type="table"}), as part of the ongoing immunologic evaluation, the patient was tested for a DNA repair disorder in a College of American Pathologists accredited and Clinical Laboratory Improvement Amendments certified laboratory (Diagnostic Molecular Pathology and DNA Repair Clinical Testing Laboratory, University of California at Los Angeles) ([@B3], [@B4]). Briefly, peripheral blood lymphocytes were immortalized *in vitro* with Epstein-Barr virus. Once a persistent lymphoblastoid cell culture (LCL) was established, various concentrations of cells were plated in 96-well plates. Some of these plates were irradiated with 1 Gy, while others were kept as controls. After 2 weeks of culture, the number of surviving colonies in each plate was enumerated to determine a survival fraction. Positive and negative controls were included with each testing batch. The test revealed the presence of significant radiation sensitivity (8% survival fraction for patient LCLs), a percentage typically seen in patients with ataxia-telangiectasia.

Several diagnostic possibilities were considered at this point. The CD8^+^ T cell lymphopenia and decreased T cell proliferative responses to mitogens suggested the presence of zeta chain-associated protein of 70 kiloDaltons (ZAP70) deficiency, although the presence of hypomorphic mutations in severe combined immunodeficiency disease (SCID)-causing genes or a novel genetic defect could not be immediately excluded as possible explanations ([@B5]--[@B8]). Although ZAP70 deficiency could account for the T cell defects present in the patient, it is not known to cause radiation sensitivity, and the protein is not associated with any DNA repair pathways. On the other hand, mutations in several SCID-causing genes (i.e., *DCLRE1C, LIG4, PRKDC*, and *NHEJ1*) are known to cause radiosensitivity and could produce a unifying diagnosis. Meanwhile, other genes associated with radiosensitivity and immune deficiency merited consideration and included *ATM, NBN, MRE11A, RAD50, APTX, BLM, DKC1*, and *RNF168* ([@B9]). In fact, several of these genetic defects have been categorized together to form the clinical entity known as XCIND syndrome, which is characterized by *X*-ray hypersensitivity, *c*ancer susceptibility, *i*mmunodeficiency, *n*eurological abnormality, and *d*ouble-strand DNA breakage ([@B10]--[@B12]). Upon further testing, however, the patient was determined to have normal protein levels of ataxia-telangiectasia mutated (ATM); nibrin; meiotic recombination 11, *S. cerevisiae* homolog of, A (MRE11); RAD50; DNA ligase 4; and aprataxin by western blotting. Normal enzymatic kinase activity of the ATM protein was also confirmed.

Thus, written informed consent was obtained from the patient and her family members to participate in a Baylor College of Medicine Institutional Review Board approved protocol for whole-exome sequencing (WES) as part of the Baylor-Hopkins Center for Mendelian Genomics project at Baylor College of Medicine (Houston, TX, USA). The patient and family members also provided written informed consent to have their clinical and genetic information published in medical or scientific journals. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. WES was performed by the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) using genomic DNA extracted from whole blood. Sequencing was performed with greater than 90% coverage at a read-depth of 20× or greater. Stratified disease-associated variants were confirmed by Sanger sequencing. Methodology, CORE design, and variant selection have been previously described ([@B1], [@B13]).

Analysis of the exome data revealed the presence of two novel compound heterozygous missense variants in *ZAP70*, one in exon 12 \[c.1505C\>T (NM_001079), p.P502L\] and the other in exon 6 \[c.733G\>A (NM_001079), p.G245R\], that could explain the immunologic defects present in the patient (Table [2](#T2){ref-type="table"}). Familial cosegregation of the variants with phenotype was confirmed by Sanger sequencing (Figure [1](#F1){ref-type="fig"}). The mother was a heterozygous carrier of the exon 12 variant, and the father was a heterozygous carrier of the exon 6 variant. Two healthy sisters were also tested, and one was found to be a heterozygous carrier of the exon 12 variant. Both variants affect highly conserved residues and lead to amino acid changes that are predicted to be damaging by Combined Annotation Dependent Depletion (CADD) score (34 for c.1505C\>T and 33 for c.733G\>A) ([@B14]--[@B16]). No other variants were observed that could provide a suitable explanation for the T cell defects (Table [S1](#SM2){ref-type="supplementary-material"} in Supplementary Material).

###### 

**Variants relevant to phenotype**.

  Gene                                                                                                                                                                                 Coordinates           Zygosity   Variant reads   Total reads   ExAC MAF   PhyloP score   CADD Phred score   Exon   cDNA change   Protein change
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- ---------- --------------- ------------- ---------- -------------- ------------------ ------ ------------- ----------------
  **Variants of interest**                                                                                                                                                                                                                                                                                              
  *ZAP70*                                                                                                                                                                              Chr2:98349618_G\>A    Het        54              112           0.00003    0.9996 (C)     33                 6      c.733G\>A     p.G245R
  *ZAP70*                                                                                                                                                                              Chr2:98354242_C\>T    Het        36              64            0          0.9987 (C)     34                 12     c.1505C\>T    p.P502L
  *RNF168*                                                                                                                                                                             Chr3:196215549_C\>T   Hom        10              10            0.02       0.9837 (C)     15.07              2      c.307G\>A     p.D103N
                                                                                                                                                                                                                                                                                                                        
  **Protein-altering variants in other double-strand break DNA repair genes[^a^](#tfn2){ref-type="table-fn"} (ExAC MAF ≤0.05, PhyloP prediction = conserved, CADD Phred score ≥15)**                                                                                                                                    
                                                                                                                                                                                                                                                                                                                        
  *MLH1*                                                                                                                                                                               Chr3:37092019_G\>A    Het        55              101           0.001      0.9994 (C)     24.6               19     c.2146G\>A    p.V716M

*^a^Genes examined: APE1, [APTX]{.ul}, [ATM]{.ul}, ATMIN, [BLM]{.ul}, BRCA1, C21ORF2, C9ORF142, CDKN1A, CHD1, [DCLRE1C]{.ul}, [DKC1]{.ul}, [ERCC2]{.ul}, EXO1, FAM65B, FANCD2, HDM2, HSPBAP1, IL13RA1, INSIG1, [IP6K2]{.ul}, KAT7, KDM4B, LIG3, [LIG4]{.ul}, MDC1, MGA, [MIR34A]{.ul}, [MLH1]{.ul}, [MRE11A]{.ul}, [MSH2]{.ul}, [MSH6]{.ul}, [NABP2]{.ul}, [NBN]{.ul}, NCK1, [NHEJ1]{.ul}, PARP1, PARP10, [PMS2]{.ul}, POLM, PRKDC, [RAD9A]{.ul}, [RAD50]{.ul}, RIC8B, [RIF1]{.ul}, [RNF168]{.ul}, [SIRT1]{.ul}, SMC1A, [TERC]{.ul}, TGFB1, [TP53]{.ul}, TP53BP1, TSPAN12, UBA2, XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6, ZEB1. Genes associated with radiosensitivity in OMIM are underlined*.

*C, conserved; Het, heterozygous; Hom, homozygous; MAF, minor allele frequency*.

![**Pedigree and results from Sanger sequencing of exons 6 and 12 of *ZAP70* and exon 2 of *RNF168***.](fimmu-08-00576-g001){#F1}

Subsequent investigations of lymphocytes isolated from the patient supported the presence of ZAP70 deficiency. *In vitro* proliferation was depressed at 10% \[stimulation index (SI) = 18\] of control responses (SI = 196) to phytohemagglutinin. Proliferation after stimulation with anti-CD3 antibody was similarly impaired (patient SI = 18, control SI = 156). The response was partially rescued by incubation with phorbol 12-myristate 13-acetate and ionomycin, as previously observed in other patients with ZAP70 deficiency ([@B5]). T cell receptor excision circle levels were also extremely low (47 per 0.5 µg of DNA, normal \>400) ([@B17]). Reduced ZAP70 protein expression was demonstrated in patient lymphocytes by immunoblotting (Figure [2](#F2){ref-type="fig"}) ([@B18]). Phosphorylation of ZAP70 was diminished after co-incubation of patient lymphocytes with anti-CD3 antibody (results not shown), although it remains unclear whether this finding resulted from the overall decreased ZAP70 expression, inability to auto-phosphorylate, or both.

![**Reduced expression of ZAP70 protein**. Immunoblotting was performed to detect ZAP70 in lysates obtained from patient (P) and control (Ctrl) peripheral blood lymphocytes. Simultaneous assessment of G1α expression is shown as a loading control.](fimmu-08-00576-g002){#F2}

Further analyses were then performed to identify a genetic cause for the radiation sensitivity. We examined the 21,536 variants identified by WES for 61 genes (Table [2](#T2){ref-type="table"}) encoding molecules known or anticipated to be associated with a cellular phenotype of radiosensitivity containing protein-altering (truncating, splicing, or non-synonymous) changes. Non-synonymous variants were considered if predicted to be conserved (by PhyloP) and damaging (CADD score ≥15) ([@B14], [@B16]). Only one variant with an ExAC minor allelic frequency (MAF) below 0.01 was identified in this manner: a single heterozygous missense change in *MLH1* \[c.2146G\>A (NM_000249), p.V716M\]. While biallelic *MLH1* mutations are associated with slight radiosensitivity in cultured skin fibroblasts (Mendelian Inheritance in Man \#276300), single allelic variants in the gene are not known to produce this phenotype. As a result and because polymorphisms have been reported to be associated with radiosensitivity, we expanded the analyses to identify variants in the same 61 genes with MAFs below 0.05 ([@B19]--[@B22]). This analysis revealed only the presence of a homozygous missense variant in exon 2 of *RNF168* \[c.307G\>A, (NM_152617), p.D103N\] (Figure [1](#F1){ref-type="fig"}). Both parents were confirmed to be heterozygous carriers of the *RNF168* variant, but neither of the two siblings received a copy of the altered gene (Figure [1](#F1){ref-type="fig"}).

Background {#S2}
==========

History {#S2-1}
-------

ZAP70 deficiency was first reported in 1994 ([@B5], [@B23], [@B24]). ZAP70 plays a critical role in T cell receptor signal transduction ([@B5], [@B25]). As a result, biallelic mutations of *ZAP70* are known to produce both abnormal thymic development of T cells and defective T cell function ([@B5], [@B26]). Because ZAP70 is highly expressed in CD8^+^ T cells and NK cells, loss of function can lead to recurrent and severe viral infections.

Radiosensitivity, immunodeficiency, dysmorphic features, and learning difficulties (RIDDLE) syndrome (Mendelian Inheritance in Man \#611943) was first described in 2007 ([@B27]). The condition was ultimately determined to be caused by biallelic mutations in *RNF168* ([@B27], [@B28]). RNF168 is a ubiquitin-ligase ring-finger protein that plays an important role in the ubiquitin-dependent DNA damage response ([@B9], [@B29]). After recognition of a double-stranded DNA break by ATM, MRE11, RAD50, and nibrin, RNF168 is recruited to the site by mono- or di-ubiquitinated histone H2A motifs. In addition, in combination with UBC13, it also directly ubiquitinates H2A during this process. RNF168 then extends the histone modifications, forming polyubiquitin chains to recruit BRCA1 and 53BP1, which facilitate DNA repair.

Review of Similar Cases {#S2-2}
-----------------------

ZAP70 deficiency results in a spectrum of immune deficiency or dysregulation ranging from atopy, autoimmunity, and late-onset combined immunodeficiency to severe, combined T and B cell deficiency from birth ([@B6], [@B24], [@B30], [@B31]). Many mutations have been identified in the gene, impacting the protein in several domains (Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material, as reported in the Human Gene Mutation Database and Mendelian Inheritance in Man). Complete deficiency of protein expression results in severe immune deficiency that results in marked susceptibility to infections within the first few months of life ([@B26]). Hypomorphic mutations produce overall T cell lymphopenia, reduced T cell function, and later-onset presentation of clinical disease, as seen in our patient ([@B26], [@B31]). In all cases, CD8^+^ T cell lymphopenia is present.

Two patients with *RNF168* deficiency have been reported to date ([@B27], [@B32]). In the first, immune deficiency was characterized by low serum IgG levels ([@B27]). The other patient had IgA deficiency but normal serum IgG levels ([@B32]). Both patients exhibited infectious susceptibility in a similar manner to our patient. In RNF168-deficient mice, the immunologic defects are more pronounced ([@B33]). The first patient was reported to have learning difficulties, but the second had normal intelligence. Our patient currently lives with her parents but functions independently. She recently completed a bachelor's degree in art and psychology. Both previously reported individuals also had short stature, motor deficits or ataxia, dysmorphic facial features or microcephaly, and radiosensitivity. Of these additional features, our patient exhibited only radiosensitivity. That said, her severe radiation hypersensitivity suggests that the detected *RNF168* variant may be phenotypically relevant and impactful. The mutations in the 2 previously reported patients are highly deleterious (compound heterozygous frameshift changes leading to premature stop codons in the first patient and a homozygous p.R131X mutation in the second, see Figure [S1](#SM1){ref-type="supplementary-material"} in Supplementary Material), perhaps accounting for the severe phenotypes. The less damaging homozygous missense variant in our patient may produce a milder phenotype consisting only of radiation sensitivity.

Discussion {#S3}
==========

Diagnosis {#S3-1}
---------

Recent advances in our understanding of the genetics and pathophysiology of immune deficiency have shown that mutations in critical pathways in T cell development and function can result in a broad spectrum of clinical phenotypes. The presented patient is, to our knowledge, not only the oldest reported patient with newly diagnosed ZAP70 deficiency but also expresses a unique blended clinical phenotype and genotype with mutations linked to two distinct immune deficiency disorders. Diagnosis of ZAP70 deficiency in adulthood is unusual, and it remains unclear whether the homozygous *RNF168* variant may have altered the classic presentation and course of ZAP70 deficiency in manners that we do not yet understand. *Vice versa*, the possibility that ZAP70 deficiency may have affected the biological impact of the *RNF168* homozygous variant cannot be excluded. The relatively high allelic frequency of this *RNF168* variant (0.02 in the ExAC database), especially among the Hispanic population (0.19), may suggest that radiosensitivity represents a clinical phenotype that occurs more commonly than recognized, perhaps because it is rarely tested. Indeed, it has been recognized that 20--40% of apparently healthy individuals have increased radiosensitivity and impaired DNA damage repair when screened for these abnormalities ([@B34]--[@B37]). Thus, it seems possible that homozygous carriers of the *RNF168* c.307G\>A variant typically possess radiation sensitivity that is not clinically apparent. As such, this variant may have clinical implications, especially if it represents a cancer susceptibility gene defect. Meanwhile, ZAP70 is known to be expressed in B cells, although its function in these cells remains poorly understood ([@B38]--[@B40]). If it has a role in B cell survival, particularly after a critical insult, such as ionizing radiation-induced DNA damage, loss of ZAP70 function could result in augmented radiation sensitivity, as assessed by the clinical *in vitro* DNA repair disorder assay. This hypothesis merits further future investigations.

Treatment {#S3-2}
---------

With the identification of the variants in *ZAP70* and *RNF168*, the patient has been referred for evaluation for potentially curative allogeneic hematopoietic stem cell transplantation (HSCT). Elements favoring this approach include the poor quality of life (due to the skin problems and significant medical support consisting of IgG supplementation; antibiotic, antifungal, and antiviral therapy or prophylaxis; and IFN-γ for HPV infection) and continued oncologic risk. On the other hand, this patient has survived into the third decade of life. While allogeneic HSCT is recommended to occur as early as possible for children with *ZAP70* deficiency to prevent fatal infectious complications, the current age of the patient makes the potential survival benefit from allogeneic HSCT less clear ([@B41]). In addition, she has considerable transplantation risks, including suppressed HPV and cryptococcal infections, absence of a fully HLA-matched donor, active skin inflammation that may increase the risk of skin graft-versus-host disease, radiation sensitivity, and advanced age.

Concluding Remarks {#S4}
==================

In summary, we report the oldest individual diagnosed with ZAP70-related primary immune deficiency. In addition, through WES, we were able to identify the presence of potentially pathogenic mutant alleles at two loci, resulting in a blended phenotype. Blended phenotypes have been reported to occur in about 5--7% of individuals tested by WES with a higher incidence (11%) in patients with PIDDs ([@B1], [@B42]--[@B45]). In this patient, WES demonstrated compound heterozygosity for two novel mutations in *ZAP70* and homozygosity for a missense variant *RNF168*, which may confer radiation sensitivity. The finding of sequence alterations in two distinct disease genes with a blended clinical phenotype of combined immunodeficiency and radiation hypersensitivity has not been reported in the literature. This case highlights the importance of examining for mutations in multiple loci beyond focusing upon single likely candidate genes. It strongly suggests the utility of WES and comprehensive and genomic testing for patients with PIDDs, particularly for patients who exhibit atypical clinical features, to exclude the presence of additional molecular defects that may have implications concerning various approaches for therapy ([@B1]). As such, multilocus genomic variation and the coexistence of two underlying genotypic abnormalities in this individual also draw attention to the clinical complexity of managing patients with such distinct or overlapping molecular phenotypes ([@B45]).
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###### 

**Known mutations in the (A) ZAP70 and (B) RNF168 proteins, as reported in the Human Gene Mutation and Mendelian Inheritance in Man databases**. Amino acid positions are marked above and mutations are shown below each protein using dotted lines. **(A)** ZAP70 protein domains are labeled within the shaded boxes. Patient mutations are designated by arrows above the protein. Note that the figure does not include the known IVS7 c.837 + 121G\>A, IVS12 c.1624-11G\>A, and c. 836_837delAT mutations. **(B)** RNF168 protein domains are labeled above the amino acid positions. Abbreviations: RING, really interesting new gene finger; LRM, LR motif; MIU, motif interacting with ubiquitin; UMI, ubiquitin interacting motif- and MIU-related ubiquitin binding domain. Patient mutations are designated by arrows below the protein.

###### 

Click here for additional data file.

###### 

**Other proband variants identified by WES**.

###### 

Click here for additional data file.
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